title: [Acute loss of vision during therapy of chronic hepatitis C].
abstract: A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C.
authors.affiliation: Augenklinik und Poliklinik, Universität Würzburg, Josef-Schneider-Strasse 11, Würzburg, Germany. Salgado_J@klinik.uni-wuerzburg.de
authors.forename: J P
authors.initials: JP
authors.lastname: Salgado
authors.forename: R
authors.initials: R
authors.lastname: Khoramnia
authors.forename: M M
authors.initials: MM
authors.lastname: Maier
authors.forename: C P
authors.initials: CP
authors.lastname: Lohmann
authors.forename: C
authors.initials: C
authors.lastname: Winkler von Mohrenfels
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D021621:Imaging, Three-Dimensional; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D058449:Intravitreal Injections; D008269:Macular Edema / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012170:Retinal Vein Occlusion / Q000139:chemically induced* / Q000188:drug therapy; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D015354:Vision, Low / Q000139:chemically induced* / Q000175:diagnosis; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068258:Bevacizumab; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a